SavedAdd your journal

Journals / Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi / 2020 / Cilt: 24 - Sayı: 1

Investigation of Antimicrobial and Antitubercular Activities of Some Hydrazone DerivedCompounds

Begüm EVRANOS-AKSÖZ
Fatma KAYNAK ONURDAĞ
Erkan AKSÖZ
Selda ÖZGEN ÖZGACAR
Pages
196–200
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, all compounds were determined as ineffective against Escherichia coli and Escherichia coli isolate.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A series of hydrazone derivatives were synthesized to investigate antifungal, antimicrobial and antitubercular activities.
📊
Key Findings & Data:Among the synthesized compounds B23had the best activity against Candida albicanswith 16 μg/mL MIC value and B24had the best activity against Staphylococcus aureus isolate (MRSA) with 16 μg/mL MIC value.
💡
Conclusion & Impact:However, all compounds were determined as ineffective against Escherichia coli and Escherichia coli isolate.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

A series of hydrazone derivatives were synthesized to investigate antifungal, antimicrobial and antitubercular activities. These activities were investigated against Escherichia coli, Escherichia coli isolate, Pseudomonas aeruginosa, Pseudomonas aeruginosaisolate (resistant to gentamicin), Staphylococcus aureus, Staphylococcus aureus isolate (MRSA), Enterococcusfaecalis, Enterococcusfaecalis isolate (VRE), Candida albicans, Candida krusei andMycobacteriumtuberculosis. Among the synthesized compounds B23had the best activity against Candida albicanswith 16 μg/mL MIC value and B24had the best activity against Staphylococcus aureus isolate (MRSA) with 16 μg/mL MIC value. The most effective compound against Mycobacteriumtuberculosis is found to be E9 with 32 μg/mL MIC value, achalcone derivative. However, all compounds were determined as ineffective against Escherichia coli and Escherichia coli isolate.

🔖

Cite This Article

EVRANOS-AKSÖZ, B., ONURDAĞ, F. K., AKSÖZ, E., ÖZGACAR, S. Ö. (2020). Investigation of Antimicrobial and Antitubercular Activities of Some Hydrazone DerivedCompounds. Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi, Cilt: 24 - Sayı: 1, 196–200. https://ajindex.com/articles/310447

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Tiberi, S., Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mvaba, P., McHugh, T. D., Ippolito, G., Migliori, G. B., Maeurer, M. J., Zumla, A. 2018.Tuberculosis: progress and advances in development of new drugs, treatment regimens and host-directed therapies.Lancet Infectious Disease.18(7), e183-e198. [2]Furin, J., Cox, H., Pai, M. 2019. Tuberculosis. Lancet, 393, 1642-1656. [3]Evranos-Aksöz, B. 2014. New Drug candidates in tuberculosis treatment. Turkish Bulletin of Hygiene and Experimental Biology,71(4), 207-220. [4]WHO. 2017. Global tuberculosis report, 2017. Geneva World Health Organization, https://reliefweb.int/report/world/global-tuberculosis-report-2017(Accessed date: 03.01.2020) [5]Monedero, I.,Caminero, J. A. 2010.Management of multidrug-resistant tuberculosis: an update. Therapeutic Advances in Respiratory Disease, 4, 117-127. [6]Yao, L.,LiangLiang, C.,JinYue, L.,WanMei,S.,Lili, S.,YiFan, L.,HuaiChen, L.2019. Ambient air pollution exposures and risk of drug-resistant tuberculosis. Environment International,124, 161-169. [7]Tong, S. Y.,Davis, J. S.,Eichenberger, E.,Holland, T. L.,Fowler, V.G. 2015. Staphylococcus aureusinfections: epidemiology, pathophysiology, clinical manifestations, and management. Clinical Microbiology Reviews,28(3), 603-661. [8]Rasigade, J. P., Vandenesch, F. 2014.Staphylococcus aureus: a pathogen with still unresolved issues. Infection Genetic Evolution,21, 510-514. [9]Sancak, B. 2011. Staphylococcus aureusand antibiotic resistance. Bulletin of Microbiology, 45(3), 565-576. [10]Bradley, S. F. 2002. Staphylococcus aureusinfections and antibiotic resistance in older adults.Clinical Infectious Diseases,34, 211-216. [11]Xu, M.,Wu, P., Shen, F., Ji, J., Rakesh, K. P. 2019. Chalcone derivatives and their antibacterial activities: current development.Bioorganic Chemistry, 91, 103-133. [12]Çetinkaya Şardan, Y. MRSA as a causative agent of nosocomial infection: prevention and control.İchastaliklaridergisi.org/managete/fu_folder/2007-03/html/2007-14-3-161-167.htm (Accessed date: 15.12.2019). [13]Thomer, L.,Schneewind, O.,Missiakas, D. 2016. Pathogenesis of Staphylococcus aureusbloodstream infections. Annual Review of Pathology,11, 343-364. [14]Lowy F. D. 1998. Staphylococcus aureusinfections.The New England Journal of Medicine,20, 339(8), 520-532. [15]Sardi, J. C. O., Scorzoni, L., Bernardi, T., Fusco-Almeida, A. M., Mendes Giannini, M. J. S. 2013. Candida species: current epidemiology, patho